Therapeutic effect of levosimendan combined dobutamine on refractory heart failure
- VernacularTitle:左西孟旦联合多巴酚丁胺对难治性心力衰竭患者的疗效
- Author:
Jun HE
- Keywords:
Heart failure;
Levosimendan;
Dobutamine
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2017;26(3):320-323
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore therapeutic effect of levosimendan combined dobutamine on refractory heart failure (RHF).Methods: A total of 90 RHF patients, who were treated in our hospital from Apr 2014 to Oct 2015, were selected.According to random number table, patients were randomly and equally divided into dobutamine group and combined treatment group (received dobutamine combined levosimendan).Cardiac function improvement after treatment,and adverse reactions during treatment were compared between two groups.Results: After treatment, cardiac function improvement rate of combined treatment group was significantly higher than that of dobutamine group (86.7% vs.60.0%), P=0.02.Compared with before treatment, after treatment, there was significant reduction in dyspnea score, and significant rise in LVEF and stroke votume(SV) in both groups (P<0.05 or <0.01);compared with dobutamine group after treatment, there was significant reduction in dyspnea score [(1.58±0.78) scores vs.(1.02±0.47) scores], and significant rise in LVEF [(42.61±7.10)% vs.(50.21±7.82)%] and SV [(57.62±14.63)ml vs.(64.21±15.12)ml] in combined treatment group, P<0.05 or <0.01.Hypotension, myocardial ischemia and arrhythmia etc.occurred in both groups, but there was no significant difference in incidence rate of total adverse reactions (P>0.05).Conclusion: Levosimendan combined dobutamine possess significant therapeutic effect on refractory heart failure and safety is good, which is worth extending.
